Median overall survival was 251 months ( 95 % CI 192-not reached ) in the dabrafenib and trametinib group versus 187 months ( 152-237 ) in the dabrafenib only group ( hazard ratio [ HR ] 071 , 95 % CI 055-092 ; p = 00107 ) .